 |
|
|
|
 |
|
|
| Article 1 to 10 out of 16 concerning Oncolytics Biotech Inc
|
-
Oncolytics Biotech Inc. Appoints Senior Vice President, Global Licensing and Business Development
(15 Dec 2009)
Oncolytics Biotech Inc. announced the appointment of Dr. Alan Warrander to the role of Senior Vice President, Global Licensing and Business Development.In his 32-year career, Dr. Warrander has held a number of positions within the biotechnology and ...
-
Oncolytics Biotech Inc. Announces Issuance of 33rd U.S. Patent
(29 Oct 2009)
Oncolytics Biotech Inc. announced that it has been granted its 33rd U.S. Patent, No. 7,608,257, entitled "Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells With a Virus." The patent claims cover methods of using reovirus in ...
-
Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients
(04 Sep 2008)
Oncolytics Biotech Inc. announced that following U.S. Food and Drug Administration (FDA) review, the Company is initiating a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin ...
-
Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN/Docetaxel Trial
(13 Aug 2008)
Oncolytics Biotech Inc. has completed patient enrolment in the dose escalation portion of its U.K. clinical trial to evaluate the anti-tumour effects of systemic administration of REOLYSIN(R) in combination with docetaxel (Taxotere(R)) in patients ...
-
Oncolytics Biotech Announces U.K. Phase II Clinical Trial Investigating REOLYSIN in Combination with Paclitaxel and Carboplatin
(16 May 2008)
Oncolytics Biotech Inc. announced that that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for its Clinical Trial Application (CTA) to begin a Phase II clinical trial using intravenous ...
-
Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent
(31 Jan 2008)
Oncolytics Biotech Inc. has been granted Canadian Patent 2,408,251 entitled "Clearance of Neoplastic Cells from Mixed Cellular Compositions using Viruses." The claims describe methods of selectively removing cancer cells ex vivo from blood stem ...
-
Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
(06 Sep 2007)
Oncolytics Biotech Inc. announced that it has been granted U.S. Patent 7,264,798 entitled "Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells with a Virus." The claims describe a method of using reovirus to prevent Ras-activated ...
-
Oncolytics Biotech Inc. Announces Issuance of Patent for Treatment of Cellular Proliferative Disorders
(09 Aug 2007)
Oncolytics Biotech Inc. today announced that it has been granted U.S. Patent 7,252,817 entitled "Viruses for the Treatment of Cellular Proliferative Disorders." The claims cover the use of modified herpes simplex viruses (HSV) to treat cellular ...
-
U.S. NCI Files for Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN
(16 May 2007)
Oncolytics Biotech Inc. announced that the U.S. National Cancer Institute (NCI) has filed a protocol with the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical trial for patients with metastatic melanoma using systemic administration of ...
-
Oncolytics Biotech Inc. Successfully Completes Initial Scale Up of Manufacturing Process for REOLYSIN
(02 May 2007)
Oncolytics Biotech Inc. announced that it has successfully completed initial scale up of its manufacturing process for REOLYSIN(R). The process improvements and scale up to 40-litre batch size has resulted in increased total yields, which are a ...
Additional information
Oncolytics Biotech Inc
Calgary, AB, Canada
Company
|
|
|
|
|
|
Top
